Market Overview

Corporate Reputation of Pharma Companies 2017-2018 - Patient Perspective of 86 German Patient Groups -


The "The
Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective
of 86 German Patient Groups"
report has been added to's

German patient groups have traditionally been suspicious of
pharma ...

The relationship between patient groups in Germany and the pharma
industry is, in one way at least, more complex than in other countries.
Because German people pay a significant proportion of their income
towards their healthcare, German citizens-and the patient groups
representing them-inevitably suspect for-profit healthcare companies of
wishing to exploit the German model of funding national healthcare by
charging ever higher prices for their products.

Evidence for such suspicion and distrust is readily seen in the fact
that fewer patient groups in Germany maintain working partnerships with
pharma than do patient groups from almost any other country.

39% of 2017's respondent German patient groups stated that the pharma
industry as a whole had an Excellent or Good reputation-the highest
percentage ever attained from German patient groups [see chart 3]. The
equivalent figure in 2017 among patient groups worldwide, though, was
higher, at 43%.

Key Topics Covered:

  1. Executive Summary
  2. Patient-Group Relationships With Pharma, 2017
  3. Industry-Wide Findings, 2017
  4. Rankings Of The 19 Pharma Companies, 2017 V. 2016 Among German Patient
    Groups Familiar With The Companies
  5. Positioning Of Six Pharma Companies, 2017 V. 2016 Among German Patient
    Groups That Work/Partner With The Companies
  6. Profiles Of The 19 Companies, 2017

Companies Mentioned

  • Abbvie
  • Amgen
  • Astrazeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Grnenthal
  • Gsk
  • Janssen
  • Merck & Co
  • Merck Kgaa
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Takeda

For more information about this report visit

View Comments and Join the Discussion!